Evidence map›Paper›PMID 30679803›Full record

ArticleLeukemia2019

Implementation of standardized variant-calling nomenclature in the age of next-generation sequencing: where do we stand?

Ann-Kathrin Eisfeld, James S Blachly, Krzysztof Mrózek, Jessica Kohlschmidt, Christopher J Walker, Albert de la Chapelle, Clara D Bloomfield

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A Boolean algebra for genetic variants.Bioinformatics (Oxford, England) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ann-Kathrin Eisfeld *The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. ann-kathrin.eisfeld@osumc.edu.
James S Blachly *The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-4275-5562
Krzysztof MrózekThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. krzysztof.mrozek@osumc.edu.
Jessica KohlschmidtThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Christopher J WalkerThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Albert de la ChapelleThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-9345-9248
Clara D BloomfieldThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. clara.bloomfield@osumc.edu.

Funding

ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D, MARCUCCI, GUIDO · 2014 to 2018
$3.4M
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA180861
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Genetic VariationHigh-Throughput Nucleotide SequencingHumansReference StandardsSequence Analysis, DNA

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.